Report Detail
Global Neuroblastoma Treatment Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
- RnM4655219 |
- 05 December, 2025 |
- Global |
- 90 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Neuroblastoma Treatment Drugs market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient"s age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The market for neuroblastoma treatment drugs is showing steady growth, benefiting from advances in medical technology and research. The market size is gradually expanding, with drug sales increasing year by year. These drugs have specific uses in neuroblastoma patients, primarily aiming to reduce tumor volume, alleviate symptoms, and enhance survival rates by targeting tumor cells. Future developments may involve more personalized treatment approaches, combining targeted therapies and immunotherapies to improve efficacy while minimizing adverse drug reactions.
This report is a detailed and comprehensive analysis for global Neuroblastoma Treatment Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Neuroblastoma Treatment Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neuroblastoma Treatment Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neuroblastoma Treatment Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Neuroblastoma Treatment Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuroblastoma Treatment Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuroblastoma Treatment Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Neuroblastoma Treatment Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Cyclophosphamide
Dinutuximab
Naxitamab
Doxorubicin Hydrochloride
Vincristine Sulfate
Other
Market segment by Application
Hospital
Clinic
Other
Major players covered
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroblastoma Treatment Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neuroblastoma Treatment Drugs, with price, sales quantity, revenue, and global market share of Neuroblastoma Treatment Drugs from 2020 to 2025.
Chapter 3, the Neuroblastoma Treatment Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Treatment Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Neuroblastoma Treatment Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neuroblastoma Treatment Drugs.
Chapter 14 and 15, to describe Neuroblastoma Treatment Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Neuroblastoma Treatment Drugs Consumption Value by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Cyclophosphamide
- 1.3.3 Dinutuximab
- 1.3.4 Naxitamab
- 1.3.5 Doxorubicin Hydrochloride
- 1.3.6 Vincristine Sulfate
- 1.3.7 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Neuroblastoma Treatment Drugs Consumption Value by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Hospital
- 1.4.3 Clinic
- 1.4.4 Other
- 1.5 Global Neuroblastoma Treatment Drugs Market Size & Forecast
- 1.5.1 Global Neuroblastoma Treatment Drugs Consumption Value (2020 & 2024 & 2031)
- 1.5.2 Global Neuroblastoma Treatment Drugs Sales Quantity (2020-2031)
- 1.5.3 Global Neuroblastoma Treatment Drugs Average Price (2020-2031)
2 Manufacturers Profiles
- 2.1 United Therapeutics
- 2.1.1 United Therapeutics Details
- 2.1.2 United Therapeutics Major Business
- 2.1.3 United Therapeutics Neuroblastoma Treatment Drugs Product and Services
- 2.1.4 United Therapeutics Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.1.5 United Therapeutics Recent Developments/Updates
- 2.2 Y-mAbs Therapeutics
- 2.2.1 Y-mAbs Therapeutics Details
- 2.2.2 Y-mAbs Therapeutics Major Business
- 2.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
- 2.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
- 2.3 EUSA Pharma
- 2.3.1 EUSA Pharma Details
- 2.3.2 EUSA Pharma Major Business
- 2.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
- 2.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.3.5 EUSA Pharma Recent Developments/Updates
- 2.4 ANI Pharmaceuticals
- 2.4.1 ANI Pharmaceuticals Details
- 2.4.2 ANI Pharmaceuticals Major Business
- 2.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
- 2.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.4.5 ANI Pharmaceuticals Recent Developments/Updates
- 2.5 Baxter Healthcare
- 2.5.1 Baxter Healthcare Details
- 2.5.2 Baxter Healthcare Major Business
- 2.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
- 2.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.5.5 Baxter Healthcare Recent Developments/Updates
- 2.6 Ingenus Pharmaceuticals
- 2.6.1 Ingenus Pharmaceuticals Details
- 2.6.2 Ingenus Pharmaceuticals Major Business
- 2.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
- 2.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
- 2.7 Pfizer
- 2.7.1 Pfizer Details
- 2.7.2 Pfizer Major Business
- 2.7.3 Pfizer Neuroblastoma Treatment Drugs Product and Services
- 2.7.4 Pfizer Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.7.5 Pfizer Recent Developments/Updates
- 2.8 Hikma Pharmaceuticals
- 2.8.1 Hikma Pharmaceuticals Details
- 2.8.2 Hikma Pharmaceuticals Major Business
- 2.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
- 2.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
- 2.9 Teva Pharmaceuticals
- 2.9.1 Teva Pharmaceuticals Details
- 2.9.2 Teva Pharmaceuticals Major Business
- 2.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
- 2.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.9.5 Teva Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Neuroblastoma Treatment Drugs by Manufacturer
- 3.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Manufacturer (2020-2025)
- 3.2 Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2020-2025)
- 3.3 Global Neuroblastoma Treatment Drugs Average Price by Manufacturer (2020-2025)
- 3.4 Market Share Analysis (2024)
- 3.4.1 Producer Shipments of Neuroblastoma Treatment Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2024
- 3.4.2 Top 3 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2024
- 3.4.3 Top 6 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2024
- 3.5 Neuroblastoma Treatment Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Neuroblastoma Treatment Drugs Market: Region Footprint
- 3.5.2 Neuroblastoma Treatment Drugs Market: Company Product Type Footprint
- 3.5.3 Neuroblastoma Treatment Drugs Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Neuroblastoma Treatment Drugs Market Size by Region
- 4.1.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2020-2031)
- 4.1.2 Global Neuroblastoma Treatment Drugs Consumption Value by Region (2020-2031)
- 4.1.3 Global Neuroblastoma Treatment Drugs Average Price by Region (2020-2031)
- 4.2 North America Neuroblastoma Treatment Drugs Consumption Value (2020-2031)
- 4.3 Europe Neuroblastoma Treatment Drugs Consumption Value (2020-2031)
- 4.4 Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value (2020-2031)
- 4.5 South America Neuroblastoma Treatment Drugs Consumption Value (2020-2031)
- 4.6 Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value (2020-2031)
5 Market Segment by Type
- 5.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2020-2031)
- 5.2 Global Neuroblastoma Treatment Drugs Consumption Value by Type (2020-2031)
- 5.3 Global Neuroblastoma Treatment Drugs Average Price by Type (2020-2031)
6 Market Segment by Application
- 6.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2020-2031)
- 6.2 Global Neuroblastoma Treatment Drugs Consumption Value by Application (2020-2031)
- 6.3 Global Neuroblastoma Treatment Drugs Average Price by Application (2020-2031)
7 North America
- 7.1 North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2020-2031)
- 7.2 North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2020-2031)
- 7.3 North America Neuroblastoma Treatment Drugs Market Size by Country
- 7.3.1 North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2020-2031)
- 7.3.2 North America Neuroblastoma Treatment Drugs Consumption Value by Country (2020-2031)
- 7.3.3 United States Market Size and Forecast (2020-2031)
- 7.3.4 Canada Market Size and Forecast (2020-2031)
- 7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe
- 8.1 Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2020-2031)
- 8.2 Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2020-2031)
- 8.3 Europe Neuroblastoma Treatment Drugs Market Size by Country
- 8.3.1 Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2020-2031)
- 8.3.2 Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2020-2031)
- 8.3.3 Germany Market Size and Forecast (2020-2031)
- 8.3.4 France Market Size and Forecast (2020-2031)
- 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
- 8.3.6 Russia Market Size and Forecast (2020-2031)
- 8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific
- 9.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2020-2031)
- 9.2 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2020-2031)
- 9.3 Asia-Pacific Neuroblastoma Treatment Drugs Market Size by Region
- 9.3.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2020-2031)
- 9.3.2 Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2020-2031)
- 9.3.3 China Market Size and Forecast (2020-2031)
- 9.3.4 Japan Market Size and Forecast (2020-2031)
- 9.3.5 South Korea Market Size and Forecast (2020-2031)
- 9.3.6 India Market Size and Forecast (2020-2031)
- 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
- 9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America
- 10.1 South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2020-2031)
- 10.2 South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2020-2031)
- 10.3 South America Neuroblastoma Treatment Drugs Market Size by Country
- 10.3.1 South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2020-2031)
- 10.3.2 South America Neuroblastoma Treatment Drugs Consumption Value by Country (2020-2031)
- 10.3.3 Brazil Market Size and Forecast (2020-2031)
- 10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa
- 11.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2020-2031)
- 11.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2020-2031)
- 11.3 Middle East & Africa Neuroblastoma Treatment Drugs Market Size by Country
- 11.3.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Country (2020-2031)
- 11.3.2 Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Country (2020-2031)
- 11.3.3 Turkey Market Size and Forecast (2020-2031)
- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Market Dynamics
- 12.1 Neuroblastoma Treatment Drugs Market Drivers
- 12.2 Neuroblastoma Treatment Drugs Market Restraints
- 12.3 Neuroblastoma Treatment Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Neuroblastoma Treatment Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Neuroblastoma Treatment Drugs
- 13.3 Neuroblastoma Treatment Drugs Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Neuroblastoma Treatment Drugs Typical Distributors
- 14.3 Neuroblastoma Treatment Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Neuroblastoma Treatment Drugs. Industry analysis & Market Report on Neuroblastoma Treatment Drugs is a syndicated market report, published as Global Neuroblastoma Treatment Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of Neuroblastoma Treatment Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
